Back
Corporate News
Alembic Pharmaceuticals’ revenue from operations rose 26% to Rs 2150 crore in Q1 2026
04-Aug-2026, 03:24
Alembic Pharmaceuticals Limited reported consolidated revenue from operations increased by 26% to Rs 2150 crore for the quarter ended June 30, 2026, with a profit after tax of Rs 173 crore, up 12% year-on-year, according to a press release. The company’s US formulation business grew by 49% to Rs 778 crore, driven by seven new product launches, while its India branded business increased 7% to Rs 642 crore, and the API business grew by 33% to Rs 346 crore.
Alembic Pharmaceuticals Limited reported consolidated revenue from operations increased by 26% to Rs 2150 crore for the quarter ended June 30, 2026, with a profit after tax of Rs 173 crore, up 12% year-on-year, according to a press release. The company’s US formulation business grew by 49% to Rs 778 crore, driven by seven new product launches, while its India branded business increased 7% to Rs 642 crore, and the API business grew by 33% to Rs 346 crore.